TLDR: The convergence of Superintelligence (SI) and synthetic biology is turning biology into an engineering discipline. Colossal Biosciences built an end-to-end platform for that work and proved it in public when it revived the dire wolf, and designed the woolly mouse. Today I’m proud to announcing NeoGenesis Capital, in partnership with Yianni Psaltis, PhD, investing in Colossal and the myriad of future companies built on its platform.
For the past two decades, genetic engineering was slow, narrow and expensive. You could edit a gene, maybe a few. Designing an organism was science fiction. The distance between reading life and writing it was the defining limit of the field, and most people assumed it would stay that way for decades.
It didn’t.
The cost of sequencing a human genome has fallen from about $100 million in 2001 to roughly $200 today. That’s a 500,000-fold drop, which makes Moore’s Law look slow. AI can now model what a change to a genome will do before anyone touches a cell. Multiplex editing can write dozens of those changes at once. Stack those curves and you get something new: the ability to design living products in silico… how they grow, how they function, and how they look, and then making them real.
And the biggest players in science see it coming. Last week the Chan Zuckerberg Biohub, the Department of Energy, the NIH, Google DeepMind, Isomorphic Labs and Meta committed $1.8 billion to generate the data for an AI “virtual cell.”
“We spent the last half century learning to read life. The next decade is about designing it, writing it and producing it.”
WHY I WROTE ONE OF THE FIRST CHECKS
In 2021, I was among the first investors in Colossal Biosciences, the company Ben Lamm and George Church founded to bring back the woolly mammoth. (Yes, everyone asks about Jurassic Park. Ben’s answer: there’s no viable dinosaur DNA left, so relax.)
I said yes because of the two of them. George is as close as we have to the father of synthetic biology. Ben is one of the best builders I know; he had started and sold five companies before Colossal. I’ve spent 30 years running XPRIZE, and I have never once seen a team regret aiming too high. A team that sets out to resurrect a species is aiming about as high as you can.
I expected a Moonshot. What I didn’t expect was that the platform underneath the Moonshot would matter more than the animal.
The world saw the headlines: the woolly mouse in March 2025 (the fluffiest proof of concept in scientific history), then Romulus, Remus and Khaleesi, the first dire wolves in more than 12,000 years, built with 20 edits across 14 genes. In May 2026, chicks hatched from a fully artificial egg, an early step toward the moa and the dodo. Yet, the real magic sits underneath.
To bring back a species, Colossal had to build a single, end-to-end system that can read a genome, use AI to model a desired change, write that change with multiplex editing, grow the organism and scale the process. Each of those steps used to be a separate discipline, in a separate lab, on a separate timeline. Colossal brought them into one workflow and demonstrated it in public, again and again.
WHAT THIS CAPABILITY COULD MAKE POSSIBLE
When you can design biology, the list of problems that become solvable gets very long, very fast. A few examples of what this platform could unlock:
Food: crops engineered to withstand drought and disease, feeding a hungrier, hotter world.
Health security: tools that track pathogens as they evolve, to help stop the next pandemic before it starts.
The environment: engineered enzymes that break down microplastics, wherever they are.
Biodiversity: reproductive technologies that could help pull endangered species back from the brink.
We call these living products: biology designed, built and scaled with the discipline of engineering. My favorite side effect is harder to measure. Somewhere right now, a 10-year-old is watching a dire wolf howl on YouTube and deciding to become a geneticist.
This is what abundance looks like when it’s written in DNA.
WHY NEOGENESIS
A capability like this doesn’t stay inside one company. Colossal has already spun out Form Bio (software for scientists), Breaking (microbes that digest plastic), Astromech (a biology model that learns from 3.8 billion years of evolution), two more companies in stealth and a bunch more coming in longevity, fertility, agriculture and AI-native genetic design.
Each of these companies starts with something rare in biotech: tools that have already worked in public, and a team that has used them.
Yianni and I wanted to help accelerate this tech, so we created NeoGenesis Capital.
We made one deliberate choice: go deep on a single platform rather than spread small bets across the whole field. It’s the same instinct behind XPRIZE. Find the most audacious team on the planet and help it go faster.
“Find the most audacious team on the planet, then help them go faster.”
WHAT THIS MEANS FOR YOU
If you read this newsletter, you know the pattern: a technology gets digitized, looks deceptively slow for years, and then goes exponential. Biology is entering that curve right now. Here’s what that means, depending on where you sit:
If you’re an entrepreneur: every industry that touches a living thing (food, materials, medicine, pets, beauty) is about to get a programmable layer. Ask what you’d build if biology behaved like software.
If you’re an executive: put synthetic biology on your five-year roadmap now, while the best partnerships are still easy to get.
If you’re a student: learn biology and AI together. The most valuable scientists of the next decade will speak both languages.
If you’re a parent: show your kids the dire wolf videos. Wonder is the gateway drug to science.
Yianni and I spent the past year building NeoGenesis quietly. Today we’re saying it out loud.
One last question for you: if you could write one new organism into existence, what would it be? Tell us in the comments. (Ben has a very long list.)
To a future of abundance,
Peter
Disclosure: We are co-founders of NeoGenesis Capital and have a financial interest in the firm. Peter is also an investor in Colossal Biosciences. Colossal and Ben Lamm hold no ownership or financial interest in NeoGenesis Capital. This post is not an offer to sell or a solicitation of an offer to buy any security; NeoGenesis Capital has already held its initial closing and is not soliciting any investors publicly. Any offering by a fund management by NeoGenesis Capital is made only to eligible investors through definitive offering documents.



The convergence of AI and synthetic biology is fascinating. But I think the next major challenge goes beyond designing living systems — it is making their behaviour predictable, traceable and verifiable.
Biology may become programmable, but unlike software, living systems evolve, interact with their environment and can produce unexpected outcomes.
We need an architecture that connects biological intent → models → constraints → experiments → evidence → validation, with explicit boundaries between what AI predicts, what experiments establish, and what we can safely authorize.
This is a direction we're exploring with GraphModel: making domain knowledge, constraints, provenance and evidence computationally explicit, rather than treating an AI-generated design as inherently trustworthy.
The real breakthrough will be when we can not only design living systems, but also establish the conditions under which their behaviour can be trusted.
A tardigrade edited to have a nitroplast and/or chloroplast